When did Avantor go public?
Avantor, a leading global provider of mission-critical products and services to customers in the life sciences, advanced technologies, and applied materials industries, officially completed its initial public offering on May 17, 2019. The company priced its shares and began trading on the New York Stock Exchange under the ticker symbol AVTR, raising significant capital to strengthen its balance sheet and fund strategic acquisitions.
Related FAQs
Evaluating Avantor (ticker AVTR) as an investment involves analyzing its revenue stabilization following post-pandemic inventory corrections, debt leverage ratios, and long-term secular growth drivers in biopharma research.
Yes, Avantor operates as a profitable enterprise, consistently generating substantial revenues and positive earnings through its global sales of specialized materials, laboratory supplies, and equipment.
Yes, Avantor underwent a planned leadership transition when former CEO Michael Stubblefield stepped down from his position. The company officially appointed Emmanuel Ligner as the new President and Chief Executive Officer, effective in August 2025.
Avantor, Inc. (NYSE: AVTR) trades at $13.67 per share.
Avantor is not currently involved in any active corporate acquisition or buyout agreements, operating instead as an independent, publicly traded enterprise on the New York Stock Exchange.
Avantor Inc. stands as a massive, multi-billion-dollar global life sciences enterprise and a premier provider of mission-critical products, specialized chemicals, and laboratory services.
Avantor maintains an established corporate presence within major large-cap indices and prominent business rankings reflecting its massive multi-billion-dollar annual revenue generation.
Avantor encountered securities litigation and investor scrutiny following unexpected operational headwinds, supply chain disruptions, and financial reporting adjustments that impacted revenue growth forecasts within its laboratory products and biopha...
Examining the stock volatility of American Express Company—a premier global payments and financial services corporation—shows a moderate volatility profile aligned closely with the broader financial sector.
Wall Street consensus price targets for Avantor, Inc. (AVTR) reflect institutional evaluations of life sciences industry demand, laboratory reagent sales, bioproduction raw material requirements, and operational margin enhancements.
Wall Street analyst consensus ratings for Avantor typically feature a mix of hold and moderate buy recommendations, balancing its vital role as a primary supplier to the life sciences industry against near-term biopharma spending caution.
Avantor, a global provider of mission-critical products and services to life sciences and advanced technology industries, has roots tied to several historic chemical entities.
Avient Corporation maintains a solid reputation as a leading provider of specialized and sustainable material solutions, including specialty engineered materials, advanced composites, and color systems.
Executive compensation for Ashish Khandpur, serving as the President and Chief Executive Officer of Avient Corporation (a specialized polymer and materials science enterprise), reflects industrial manufacturing benchmarks.
Baxter International, a major global medical products and healthcare company, carries a substantial debt portfolio resulting from large-scale corporate acquisitions, structural transformations, and ongoing operational investments.
Yes, Avantor is recognized as a Fortune 500 company, reflecting its substantial scale, annual revenue, and prominent position within the global industrial and life sciences marketplace.
Avantor, Inc. is headquartered in Radnor, Pennsylvania, United States.
Institutional analysts tracking Avantor, Inc. (AVTR) establish a consensus 12-month average price target of approximately $12.17 per share. Individual broker forecasts range from a conservative low estimate of $7.